Patient-Centered menopause health management and menopausal hormone therapy uptake: A real-world study from a tertiary Hospital in China.

Save

Objective

To evaluate whether a patient-centered integrated menopause clinic model was associated with menopausal hormone therapy initiation, self-reported medication habits, and menopause-related knowledge among women with indications for treatment.

Methods

We retrospectively analyzed 405 women aged 40–60 years with MHT indications who attended Peking University First Hospital in 2023. Outcomes were compared between the MHT Integrated and Patient-Centered Clinic (MIPCC; n = 192) and a general menopause clinic (GMC; n = 213) after one year.

Results

MIPCC patients were slightly older and more often postmenopausal. Insomnia, reduced libido, dyspareunia, vaginal dryness, and recurrent vaginitis were more frequent in the MIPCC group. MHT initiation was higher in the MIPCC group than in the GMC group (165/192 [85.94%] vs.

94/213 [44.13%]; adjusted OR 7.60, 95% CI 4.63, 12.49). Discontinuation among initiators was numerically lower in the MIPCC group (18.29% vs. 20.21%), but no statistically significant difference was observed.

Selected self-reported medication-habit and knowledge responses were more favorable among MIPCC patients.

Conclusions

The MIPCC model was associated with higher MHT initiation and more favorable responses to selected self-reported medication-habit and knowledge items. Patient-centered menopause management may represent a useful preventive health strategy, but prospective multicenter studies are needed to confirm its effectiveness and generalizability.

Introduction

With population aging and increasing life expectancy, women spend a substantial proportion of their lives after menopause. Menopause is associated with vasomotor symptoms, sleep disturbance, genitourinary symptoms, mood changes, and long-term risks related to estrogen deficiency, including osteoporosis and cardiovascular disease. Appropriate health management during midlife therefore represents an important opportunity to maintain quality of life and support healthy aging (Church and Biagi, 2025; Appiah et al., 2021; Menopause, 2026; Gatenby and Simpson, 2024; Lancet, 2022).

MHT remains a first-line option for eligible women with climacteric symptoms and selected preventive indications (Crandall et al., 2023; Langer et al., 2021). However, the initial Women's Health Initiative findings and subsequent public discussion brought MHT risks into sharp focus, and concerns about breast cancer, cardiovascular disease, and thrombosis continue to influence patient decisions (Rossouw et al., 2002; Levy and Simon, 2024; Manson et al., 2024; Taylor and Davis, 2025). Over the past two decades, accumulating evidence has helped refine the risk-benefit assessment of MHT, but effective communication and individualized follow-up remain essential.

In this context, a structured clinic pathway is important because patients need more than a brief prescription decision. They require standardized evaluation of indications and contraindications, clear explanation of benefits and risks, and practical follow-up plans that support safe continuation or timely adjustment of therapy. These needs are difficult to meet consistently in a routine high-volume outpatient visit.

Peking University First Hospital established menopause services in 2012 and has since developed the MIPCC model to provide more systematic, patient-centered care. The model integrates multidisciplinary assessment, individualized consultation, lifestyle and nutrition guidance, medication counseling, and long-term follow-up. Integrated care models may improve patient knowledge and adherence, but real-world evidence on their effectiveness remains limited (Haleem et al., 2021; Hoeppner et al., 2021; Tandon et al., 2022).

This study compared patients managed in the MIPCC model with those attending a GMC to evaluate differences in symptoms, MHT uptake, medication habits, and menopause- and MHT-related knowledge.

The practical value of this model lies in its attempt to connect clinical assessment with patient education and follow-up. During the one-day clinic process, patients can receive focused counseling on menopausal symptoms, chronic disease prevention, bone health, sexual and urinary symptoms, and individualized MHT decision-making. This format may be particularly useful for women with multiple symptoms or strong concerns about medication safety.

The rationale for evaluating this model is practical as well as clinical. In routine outpatient settings, menopause visits are often brief, and patients may receive fragmented information about symptoms, chronic disease prevention, and MHT safety. A structured clinic may create more time for education, allow multidisciplinary input, and provide repeated contact after treatment initiation.

These features are particularly relevant for MHT, where patient preference, risk perception, and adherence strongly influence real-world outcomes.

Methods

Study design and population

This retrospective study was conducted at Peking University First Hospital, Beijing, China. The study was approved by the Institutional Review Board of Peking University First Hospital (Approval No. 2020[239]), and informed consent was obtained.

Between January and December 2023, women aged 40–60 years attending the menopause clinic were screened. Inclusion criteria were menopause within 10 years, indications for MHT, and a modified Kupperman Menopause Index (KMI) score ≥ 16 (Tao et al., 2013). The modified KMI comprised 13 symptoms: sweating/hot flushes, paresthesia, insomnia, nervousness, melancholia, vertigo, fatigue, arthralgia/myalgia, headache, palpitations, skin formication, sexual complaints, and urinary tract infection.

Each item was rated from 0 (none) to 3 (severe), multiplied by its established weight, and summed (range, 0–63) (Tao et al., 2013). Patients with contraindications to MHT, severe comorbidities, mental health symptoms requiring medication, or inability to complete follow-up were excluded.

A total of 405 eligible patients were included, including 192 in the MIPCC group and 213 in the GMC group. We compared baseline characteristics, symptom distribution, MHT initiation, discontinuation, one-year medication habits, and understanding of menopause and MHT. MHT initiation referred to treatment initiated after clinic attendance.

Discontinuation during the one-year follow-up was assessed among patients recorded as having initiated MHT. The one-year follow-up questionnaire was investigator-developed through repeated discussions with experts at the hospital. It was initially tested in a small-scale survey of patients attending our menopause clinic to explore its suitability and feasibility for outpatient use.

The questionnaire assessed knowledge of menopause-related chronic diseases, appropriate timing for MHT, benefits of MHT, major risk concerns, and medication habits including forgetting medication, self-discontinuation, difficulty adhering to treatment, and difficulty remembering medication. Data processing was double-checked by two individuals.

The comparison was intended to reflect real-world service selection rather than randomized allocation. Patients who accepted MIPCC management received the integrated model, whereas those who declined continued care in the GMC. This design allowed evaluation of the model under routine clinical conditions, but it also required careful interpretation because baseline differences between groups could influence outcomes.

All systemic MHT used in both groups was oral. Regimens included sequential estradiol/dydrogesterone (estradiol 1 or 2 mg, with dydrogesterone 10 mg during the progestogen phase), tibolone, and estradiol valerate combined with dydrogesterone or progesterone. Doses and regimens, including continuous combined or sequential schedules for estrogen-progestogen therapy, were individualized and adjusted according to menopausal status, time since menopause, and patient preference, with the aim of improving quality of life while balancing benefits and risks.

The MIPCC model consisted of a one-day clinic session involving doctors, nurses, nutritionists, clinical pharmacists, and relevant specialists in fields such as urology, cardiology, endocrinology, orthopedics, neurology, psychiatry, nutrition, rehabilitation, and pharmacology. The session included body composition analysis, blood pressure and glucose monitoring, menopause education, chronic disease education, medication safety guidance, nutrition counseling, exercise guidance, and mental and cognitive health education. Each patient also received one-on-one consultation with a menopause specialist, during which individualized management and medication plans were developed.

Follow-up visits were scheduled at 1, 2, 3, 6, 9, and 12 months, and every six months thereafter. Follow-up focused on health status, symptoms, medication responses, adherence, and treatment adjustment. Specialists from other disciplines were involved when needed.

An online communication group including physicians and nurses provided education, follow-up reminders, and responses to patient questions. Patients in the GMC received routine menopause education, nutrition and exercise guidance, and medication advice based on their health data and symptoms. Follow-up was scheduled at the same time points as in the MIPCC group, and the assessment focus was similar.

The one-day session was designed to provide a concentrated but comprehensive assessment. Educational content covered menopause-related symptoms, prevention of osteoporosis and cardiovascular disease, genitourinary syndrome of menopause, medication benefits and risks, diet, exercise, and mental health. Nutritionists and pharmacists provided practical advice that complemented the physician consultation.

When patients had complex symptoms or comorbidities, the menopause specialist arranged referral to appropriate departments.

This study was approved by the Institutional Review Board of Peking University First Hospital (Approval No. 2020[239]). All participants provided written informed consent prior to inclusion.

The study was conducted in accordance with the Declaration of Helsinki and local ethical standards.

Measures

At the initial visit, information on age, height, weight, medical history, family history, medication history, menopausal symptoms, lifestyle habits, and primary reasons for consultation was collected. This assessment occurred before clinic selection and applied to both groups. All included patients had clear indications for MHT and no contraindications.

Physicians in both groups recommended MHT and explained its potential benefits and risks. At the initial visit, the modified KMI was used to quantify menopausal symptom severity. A separate 24-item clinical checklist was used to document a broader range of menopausal symptoms and physical health concerns encountered in outpatient practice.

The checklist findings are presented in Fig. 1 and Supplementary Table S1 to provide a more comprehensive description of patients' health status during menopause. Patients with MHT indications and no contraindications received a detailed explanation of the MIPCC model, including the one-day multidisciplinary assessment, individualized counseling, and follow-up arrangements.

They were then invited to join the MIPCC model; those who declined received care in the GMC.Fig. 1Baseline distribution of 24 menopausal symptoms and physical health concerns among 405 women aged 40–60 years with MHT indications attending Peking University First Hospital in 2023. The dumbbell plot shows all 24 items of the clinical checklist, in the original checklist order, for the MHT Integrated and Patient-Centered Clinic (MIPCC; n = 192) and General Menopause Clinic (GMC; n = 213) groups.

Black filled circles indicate MIPCC and open circles indicate GMC; exact percentages are listed in the columns on the right. Connecting segments link the two group-level percentages for each item; they do not represent paired observations, changes over time, or confidence intervals. Each percentage uses the corresponding clinic group as its denominator.

These data describe symptoms and health concerns recorded at the initial visit, not changes after clinic management. The checklist provides a broader clinical description than the modified Kupperman Menopause Index and was assessed separately. Complete counts, percentages, and item-level chi-square or Fisher's exact test results are provided in Supplementary Table S1.Fig.

1

Statistical analysis

Descriptive and between-group analyses were performed using SPSS version 27.0. Normality was assessed using the Shapiro-Wilk test. Quantitative variables were non-normally distributed and are presented as medians and interquartile ranges.

Between-group comparisons used Mann-Whitney U tests for quantitative variables and chi-square or Fisher's exact tests for qualitative variables. Symptom impact scores were calculated as: (sum frequency x weight) / number of responses. Unadjusted ORs were calculated from 2 × 2 tables.

Separate multivariable logistic regression models assessed MHT initiation in all 405 participants and discontinuation among 258 initiators, adjusting for age, menopausal status, and baseline KMI. ORs with 95% CIs are reported. Regression analyses were performed using Python 3.12 and statsmodels 0.14.6.

Results

The MIPCC group was slightly older than the GMC group, with median ages of 51 (48, 53) and 49 (46, 53) years, respectively. The MIPCC group also included more postmenopausal patients than the GMC group (59.90% vs. 40.38%).

Postmenopausal duration was slightly longer in the GMC group, while KMI scores were similar between groups, indicating comparable baseline symptom severity.

At baseline, memory decline was the most common symptom among all patients, affecting 62.47% of participants. Other common symptoms included arthralgia and myalgia, insomnia, hot flushes, frequent dreaming, fatigue, reduced libido, difficulty concentrating, urinary incontinence, depression, nervousness, and vaginal dryness. Fig.

1 compares all 24 items in the baseline clinical checklist, with complete item-level results in Supplementary Table S1. Fatigue was more frequent in the GMC group, whereas insomnia, reduced libido, dyspareunia, vaginal dryness, and recurrent vaginitis were more frequent in the MIPCC group. These percentages describe symptoms and health concerns recorded at the initial visit.

The symptom profile suggests that women choosing the integrated clinic may have had more complex or sensitive concerns, especially sleep and sexual health problems. These symptoms may not always be fully addressed during a routine visit, and patients experiencing them may prefer a model that offers more time for counseling and follow-up. In contrast, common symptoms such as memory decline and musculoskeletal discomfort were widely reported across both groups.

When patients ranked the symptoms with the greatest impact on quality of life, the top symptoms were broadly similar between groups. Insomnia had the highest impact score in both groups (Fig. 2), followed by memory decline, arthralgia and myalgia, hot flashes, depression, and irritability.

These findings suggest that sleep disturbance was a major concern among eligible patients regardless of care model. Fig. 2 ranks symptoms separately within each group using weighted impact scores, which are distinct from symptom prevalence and KMI scores.Fig.

2Top ten menopausal symptoms ranked by weighted impact score among 405 women aged 40–60 years with MHT indications attending Peking University First Hospital in 2023. Horizontal bar charts show the MIPCC group in panel a (solid black bars) and the GMC group in panel b (white bars with black outlines), using identical score axes. Each symptom and its score are labeled directly.

Scores summarize patients' rankings of symptoms affecting quality of life and were calculated from ranking frequencies and weights as described in Section 2.7. Symptoms are ranked separately within each group; bars at the same position therefore do not necessarily represent the same symptom. These weighted impact scores are distinct from the symptom percentages in Fig.

1 and the modified Kupperman Menopause Index scores. The displayed sample sizes refer to the clinic cohorts (MIPCC, n = 192; GMC, n = 213), rather than symptom-specific response counts. The figure is descriptive; no between-group significance tests or variability estimates are shown.Fig.

2

MHT initiation was higher in the MIPCC group than in the GMC group (165/192 [85.94%] vs. 94/213 [44.13%]; unadjusted OR 7.41, 95% CI 4.57, 12.02). The association remained after adjustment for age, menopausal status, and baseline KMI (adjusted OR 7.60, 95% CI 4.63, 12.49).

Among MHT initiators, discontinuation was numerically lower in the MIPCC group than in the GMC group (30/165 [18.18%] vs. 19/94 [20.21%]; unadjusted OR 0.88, 95% CI 0.47, 1.68). No statistically significant between-group difference was observed before or after adjustment for age, menopausal status, and baseline KMI (adjusted OR 0.84, 95% CI 0.43, 1.63).

Age, menopausal status, and baseline KMI were not significantly associated with initiation in this model (all P > 0.05). Among patients declining MHT, tumor risk was the most common concern in both groups. Compared with the GMC group, the MIPCC group reported more favorable responses on selected medication-habit items, including frequently forgetting medication, self-discontinuation, difficulty adhering to treatment, and difficulty remembering medication.

These findings indicate that MIPCC attendance was associated with the decision to start MHT, but did not demonstrate an advantage in continuation after initiation. The difference in initiation rate was particularly large, despite the fact that breast cancer risk remained a major concern. Repeated education and direct communication with clinicians may support selected medication-taking behaviors, but their relative contributions were not assessed.

One-year questionnaire findings are presented by topic in Fig. 3, with complete item-level results in Supplementary Table S2. More MIPCC patients selected initiation within one year of menopause (60.94% vs.

46.01%) and identified relief of genitourinary syndrome of menopause and reduced cardiovascular disease risk as potential MHT benefits. Most patients in both groups selected osteoporosis prevention, whereas approximately one-third selected improved insulin resistance. Breast cancer was the most frequently reported risk concern in both groups and was more common in the MIPCC group (72.92% vs.

40.85%), despite its higher MHT initiation rate.Fig. 3Item-level responses to the menopause and menopausal hormone therapy questionnaire at one-year follow-up among 405 women aged 40–60 years with MHT indications treated at Peking University First Hospital in 2023. Panels show recognition of conditions associated with menopause (a), perceived timing for MHT initiation (b), perceived benefits of MHT (c), and concerns about MHT risks (d).

All 23 items from the corresponding questionnaire sections are shown. Black filled bars indicate MIPCC (n = 192) and white bars with black outlines indicate GMC (n = 213). Percentages are labeled for each group and use the corresponding clinic group as the denominator; all panels use a 0–100% scale.

Bars represent the proportion selecting each response, not a composite knowledge score. The risk-concern items describe patients' concerns, not observed adverse-event rates, and higher percentages do not uniformly indicate more favorable responses. Complete counts, percentages, and item-level chi-square or Fisher's exact test results are provided in Supplementary Table S2.

MHT, menopausal hormone therapy; GSM, genitourinary syndrome of menopause.Fig. 3

The low awareness of MHT-related glycemic effects suggests an area for improvement in patient education. At the same time, the high level of concern about breast cancer highlights the need for balanced risk communication. Education should not minimize patient concerns, but should explain absolute risk, treatment duration, formulation, route, timing of initiation, and individual risk factors.

Discussion

This real-world study found that MIPCC attendance was associated with higher MHT initiation and more favorable responses on selected self-reported medication-habit and menopause- and MHT-related knowledge items among eligible women. Discontinuation among initiators was numerically lower, but no statistically significant difference was observed before or after adjustment; a benefit in treatment continuation has not been demonstrated. The association with MHT initiation persisted after adjustment for age, menopausal status, and baseline KMI.

However, patient self-selection and residual confounding preclude attributing this association solely to the clinic model.

Observed differences in age, menopausal status, and symptoms may reflect differing preferences for care. The higher frequency of insomnia, reduced libido, and vaginal dryness among MIPCC patients suggests that symptom-specific concerns may influence preference for more comprehensive, individualized care. Time commitments and convenience may also influence clinic choice and access.

Because reasons for clinic choice were not systematically recorded, these remain possible explanations rather than established determinants of selection.

Sleep and sexual function-related symptoms were more frequent in the MIPCC group. Insomnia had the highest impact score in both groups, consistent with prior evidence that sleep disturbance is common during perimenopause and postmenopause (Tandon et al., 2022; Davis et al., 2023; Maki and Jaff, 2022; Stefanowski et al., 2023; Proserpio et al., 2020; Insomnia overview, 2025; Bonanni et al., 2019; Cintron et al., 2017). In clinical practice, sleep complaints often require combined assessment of vasomotor symptoms, mood, lifestyle, and medication options.

The multidisciplinary structure of MIPCC may be particularly useful for these complex symptom clusters.

The higher prevalence of reduced libido, dyspareunia, vaginal dryness, and recurrent vaginitis in the MIPCC group also deserves attention. Sexual health problems during menopause are often underreported and undertreated, especially in settings where patients may be reluctant to raise sexual concerns. Menopause services should therefore proactively assess sexual health and provide counseling, gynecological management, and referral when appropriate (Hoeppner et al., 2021; Scavello et al., 2019; Nappi et al., 2022).

Education and communication are central to the MIPCC model. Although breast cancer risk was the main concern, most MIPCC patients initiated MHT. This suggests that structured counseling may help patients understand both benefits and risks and make more informed decisions.

The relationship between MHT and breast cancer risk depends on formulation, timing, duration, and patient characteristics; therefore, risk communication should be individualized and based on current evidence (Faubion et al., 2022; Speksnijder, and ten Noever de Brauw GV, Malekzadeh A, Bisschop PH, Stenvers DJ, Siegelaar SE., 2023; Arnold et al., 2022; Lancet, 2019; Tan and Dayu, 2022).

The questionnaire findings varied by item. MIPCC patients more often selected initiation within one year of menopause and identified GSM relief and reduced cardiovascular disease risk as potential MHT benefits, but the pattern did not indicate uniformly greater knowledge across all topics. The item-level findings may provide useful exploratory information for clinic evaluation and patient counseling but should not be interpreted as a validated overall knowledge effect.

Importantly, higher concern about breast cancer in the MIPCC group should not be interpreted as poorer education. Instead, it may reflect greater awareness of the main safety issue discussed during counseling. The key clinical goal is not to eliminate concern, but to ensure that concern is informed, proportionate, and integrated into shared decision-making.

In this respect, the combination of higher concern and higher uptake may indicate more nuanced patient understanding.

More favorable responses on selected self-reported medication-habit items concern specific medication-taking behaviors. Decisions about continuing MHT may reflect multiple factors beyond the clinic model; their relative contributions were not assessed. Both groups had the same scheduled follow-up time points; MIPCC additionally provided multidisciplinary counseling and an online communication group.

These components may support medication-taking behaviors, but their individual effects were not tested. The model also requires time, staffing, and coordination. To improve scalability, clinics may need more flexible scheduling, weekend sessions, remote follow-up, or targeted clinics for common problems such as sexual health and sleep disturbance.

For health systems, the model may be most useful when applied to patients with multiple symptoms, high concern about treatment, or difficulty maintaining follow-up. A tiered approach could combine routine menopause clinics for lower-complexity patients with integrated sessions for patients needing multidisciplinary assessment. Remote education and follow-up could also preserve key components of the model while reducing time and travel burdens.

Telemedicine-based psychosocial interventions have reduced fear of cancer recurrence in cancer survivors, suggesting a potential role for remote psychological support that warrants evaluation in menopause care (Su et al., 2026).

This study has several limitations. Its retrospective, nonrandomized design leaves potential for patient self-selection and residual confounding despite adjustment for age, menopausal status, and baseline KMI. Follow-up was limited to one year, and the contributions and resource requirements of individual MIPCC components were not assessed.

The investigator-developed questionnaire underwent expert discussion and small-scale pilot testing but requires further validation. All systemic MHT was oral, and regimen-specific effects were not examined.

Because this study was conducted at a tertiary hospital with established multidisciplinary menopause services, its generalizability to other settings may be limited. Cross-institutional collaboration and resource coordination may facilitate the adaptation of new care models (Hu et al., 2026), and efforts to introduce MIPCC to other hospitals have begun. Future prospective multicenter studies should evaluate long-term outcomes, reasons for clinic choice, component-level effectiveness, and cost-effectiveness.

Randomized trials would provide stronger evidence of the model's effects and inform broader implementation.

Conclusions

The MIPCC model was associated with higher MHT initiation and more favorable responses on selected self-reported medication-habit and menopause- and MHT-related knowledge items among eligible patients. Age, menopausal status, sleep disturbance, and sexual function-related symptoms may influence patients' preference for integrated care. These findings support patient-centered menopause management as a preventive health strategy, while prospective multicenter studies are needed to confirm long-term effectiveness and scalability.

CRediT authorship contribution statement

He Huang: Writing – original draft, Visualization, Methodology, Investigation, Formal analysis, Conceptualization. Xiaoliang Men: Methodology, Investigation, Formal analysis, Conceptualization. Xiufeng Lin: Data curation.

Pei Pang: Data curation. Shifang Liu: Resources. Xinnan Hou: Resources.

Xiaorui Li: Resources. Hongyan Jin: Writing – review & editing, Supervision, Project administration, Funding acquisition.

Ethics declaration

Informed consent and patient details

Written informed consent to take part in the study and to publish the article has been obtained from all participants or their legal representatives. The privacy rights of participants have been observed.

Studies in human

This study was performed in compliance with relevant laws, regulatory frameworks and guidelines where the research took place. This study was approved by the Institutional Review Board of Peking University First Hospital. (Approval No.

2020[239])

Funding

This research was supported by National Natural Science Foundation of China under Grant (reference numbers: 62374004, 81971348, 61673024, 62333020) and the Fundamental Research Funds for the Central Universities (number: PKU2022XGK002).

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Related articles

PubMed

Dietary supplements are commonly used for menopause symptoms amid concerns about hormone therapy: a cross-sectional study.

Objective Many women use dietary supplements to manage menopause symptoms, yet patterns of use, perceived effectiveness, and information sources remain incompletely described in contemporary literature. This cross-sectional study assessed current dietary supplement use, including use specifically for menopause symptoms, and perceptions of menopausal hormone therapy (MHT) among symptomatic menopausal women aged 45–65 years. Methods An online questionnaire was administered to a self-selected sa...

PubMed

Gynecologist and Menopausal Patient Perspectives on Vaginal Hormone Therapy for the Management of the Genitourinary Syndrome of Menopause in Canada: A Real-World Survey.

Purpose The genitourinary syndrome of menopause (GSM) is common during menopause and can have a profound negative impact on quality of life. Vaginal hormone therapy (HT) is a guideline-recommended second-line treatment for GSM but its real-world utilization in Canada is poorly described in the literature. The objectives of this real-world study were to examine current patterns of practice and potential gaps in the management of GSM in Canada and to evaluate factors affecting patient satisfactio...